US Guidelines for immune tolerance induction in patients with haemophilia a and inhibitors
LA Valentino, CL Kempton, R Kruse‐Jarres… - …, 2015 - Wiley Online Library
LA Valentino, CL Kempton, R Kruse‐Jarres, P Mathew, SL Meeks, UM Reiss…
Haemophilia, 2015•Wiley Online LibraryIntroduction The development of anti‐factor VIII (FVIII) antibodies (inhibitors) is the most
serious treatment‐related complication in patients with hemophilia A, rendering standard
replacement therapy ineffective, heightening the risk for uncontrollable bleeding and
morbidity, decreasing quality of life, and increasing healthcare costs. Aim Formulate
evidence‐based guidelines for optimizing immune tolerance induction (ITI) in patients with
hemophilia A and inhibitors. Methods Results from the International ITI study and other …
serious treatment‐related complication in patients with hemophilia A, rendering standard
replacement therapy ineffective, heightening the risk for uncontrollable bleeding and
morbidity, decreasing quality of life, and increasing healthcare costs. Aim Formulate
evidence‐based guidelines for optimizing immune tolerance induction (ITI) in patients with
hemophilia A and inhibitors. Methods Results from the International ITI study and other …
Introduction
The development of anti‐factor VIII (FVIII) antibodies (inhibitors) is the most serious treatment‐related complication in patients with hemophilia A, rendering standard replacement therapy ineffective, heightening the risk for uncontrollable bleeding and morbidity, decreasing quality of life, and increasing healthcare costs.
Aim
Formulate evidence‐based guidelines for optimizing immune tolerance induction (ITI) in patients with hemophilia A and inhibitors.
Methods
Results from the International ITI study and other available evidence were used to develop guidelines for ITI.
Results
Predictors of ITI success were identified and recommendations made for ITI with regard to candidates, timing, product, regimen, monitoring, defining success, concurrent immunomodulation, duration of treatment, and bleed management before and during ITI.
Conclusion
Evidence‐based recommendations to guide treatment decisions may increase the likelihood of successful inhibitor eradication and the induction of FVIII tolerance in patients with hemophilia A who develop inhibitory antibodies.
Wiley Online Library